PATENT CLAIM ANALYSIS

Application Number: 16022275
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["424", "143100"]

Abstract:
The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.

Claim (Index 76):
The method of  claim 68 , wherein binding of the GITR-binding antibody or antigen-binding fragment to a T cell results in T cell receptor-induced signaling in a T-effector cell.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 94.0
- Lexical Diversity: 1.875
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15345182', '14665533', '12753402', '11389880', '13782656']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8306958079195611
- 35 USC 102 Novelty (BERT): 0.6502143629762124
- Combined Prediction Score: 0.8126476634252262
- Mean Citation Score: 665.3161759999998
- Max Citation Score: 682.2406
- Similarity Product: 574.1846283521891

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test